Sulprostone

Description

Sulprostone is a metabolism resistant synthetic analog of PGE₂. It is a selective agonist for EP₃ receptors with a K_i value of 0.35 nM at the human recombinant EP₃-III receptor and an IC₅₀ of 0.01 μM for the inhibition of PGE₂ binding. Sulprostone is a potent stimulator of uterine smooth muscle contractions with high abortifacient activity.

Originator

Nalador,Schering,W. Germany,1981

The Uses of Sulprostone

Sulprostone is a selective agonist of the PGE2 receptor.

The Uses of Sulprostone

antimalarial activity

The Uses of Sulprostone

Human chondrocytes³ and mouse adrenal chromaffin cells⁴ were treated with sulprostone to study the biological effects of PGE₂.

What are the applications of Application

Sulprostone is a metabolism resistant synthetic analog of PGE2 that is a selective EP3 prostanoid receptor agonist

Definition

ChEBI: Sulprostone is a prostanoid.

Manufacturing Process

9α-Hydroxy-11α,15α-bis-(tetrahydropyran-2-yloxy)-16-phenoxy-cis-5-trans- 13-ω-tetranorprostadienoicacid: To a solution of 1.6 g (3.6 mmols) (4- carbohydroxy-n-butyl)triphenylphosphonium bromide in a dry nitrogen atmosphere in 6.0 ml dry dimethyl sulfoxide was added 3.24 ml (6.5 mmols) of a 2.0 M solution of sodium methylsulfinylmethide in dimethyl sulfoxide. To this red ylide solution was added dropwise a solution of 613 mg (1.29 mmols) 2-[5α-hydroxy-3α-(tetrahydropyran-2-yloxy)-2α-(3α-tetrahydropyran-2-yloxy- 4-phenoxytrans-1-buten-1-yl)cyclopent-1α-yl] acetaldehyde, γ-hemiacetal in 5.0 ml dry dimethyl sulfoxide over a period of 20 minutes.
After an additional 2 hours stirring at room temperature, the reaction mixture was poured onto ice water. The basic aqueous solution was washed twice with ethyl acetate (20 ml) and acidified to pH 3 with 10% aqueous hydrochloric acid.
The acidic solution was extracted with ethyl acetate (3 x 20 ml) and the combined organic extracts washed once with water (10 ml), dried (MgSO4) and evaporated to a solid residue. This solid residue was triturated with ethyl acetate and the filtrate concentrated. Yield: 754 mg of 9α-hydroxy-11α,15α-bis-(tetrahydropyran-2-yloxy)-16-phenoxy-cis-5-trans-13- ωtetranorprostadienoic acid was collected.
9-Oxo-11α,15α-bis-(tetrahydropyran-2-yloxy)-16-phenoxy-cis-5-trans-13-ω- tetranorprostadienoicacid: To a solution cooled to -10°C under nitrogen of 754 mg (1.3 mmols) 9α-hydroxy-11α,15α-bis-(tetrahydropyran-2-yloxy)-16- phenoxy-cis-5-trans-13-ω-tetranorprostadienoic acid in 13 ml reagent grade acetone was added dropwise to 0.56 ml (1.41 mmols) of Jones' reagent (chromic anhydride). After 20 minutes at -10°C, 0.260 ml 2-propanol was added and the reaction mixture was allowed to stir an additional 5 minutes at which time it was combined with 75 ml ethyl acetate, washed with water (3 x 10 ml), dried (MgSO4)and concentrated to give 752 mg of 9-oxo-11α,15α-bis- (tetrahydropyran-2-yloxy)-16-phenoxy-cis-5-trans-13-ω-tetranorprostadienoic acid, which was chromatographed on silica gel using ethyl acetate as eluent to afford 505 mg of pure intermediate.
N-Methanesulfonyl-9-oxo-11α,15α-dihydroxy-5-cis-13-trans-16-phenoxy-ω- tetranorprostadienamide:To 1.0 mmols of 9-oxo-11α,15α-bis- (tetrahydropyran-2-yloxy)-16-phenoxy-cis-5-trans-13-ω-tetranorprostadienoic acid in 40 ml THF is added 2 ml triethylamine. After 15 minutes of stirring at room temperature 10.0 ml of 0.1 M methanesulfonylisocyanate in THF is added. After a further 1 hour of stirring, the reaction mixture is neutralized with acetic acid and the solvent removed by evaporation (in vacuo). The resultant residue is taken up in methylene chlorine and washed successively with water and sodium bicarbonate to yield, after drying and solvent evaporation, N-methanesulfonyl-9-oxo-11α,15α-bis-(tetrahydropyran-2-yloxy)- 16-phenoxy-cis-5-trans-13-ω-tetranorprostadienamide. This intermediate is then hydrolyzed overnight with acetic acid/water and purified by column chromatography to give the desired N-methanesulfonyl-9-oxo-11α,15α- dihydroxy-5-cis-13-trans-16-phenoxy-ω-tetranorprostadienamide.

Therapeutic Function

Contraceptive

World Health Organization (WHO)

Sultopride, a neuroleptic indicated for the treatment of acute and chronic psychoses, was introduced on the market in 1976. In the early 1990s, its use was associated with cardiac arrhythmias, some of which were fatal. This led the regulatory authority in France to take restrictive action on the product. Sultopride continues to be marketed in several other countries.

Biochem/physiol Actions

Sulprostone is an analog of prostaglandin E2 (PGE2)1 and antagonizes vasopressin-induced antidiuretic responses in cells from rat renal inner medullae by a mechanism that involves activation of Rho.2

storage

Store at -20°C